S. R. Aravind
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
S. R. Aravind has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- B. S. Dileep Kumar
Agroprocessing and Natural Products Division, National Institute for Interdisciplinary Science and Technology - Council of Scientific and Industrial Research Thiruvananthapuram, India
1 shared publication - Geethu Gopinath
Agroprocessing and Natural Products Division, National Institute for Interdisciplinary Science and Technology - Council of Scientific and Industrial Research Thiruvananthapuram, India
1 shared publication - Jubi Jacob
Agroprocessing and Natural Products Division, National Institute for Interdisciplinary Science and Technology - Council of Scientific and Industrial Research Thiruvananthapuram, India
1 shared publication - Lakshmi Sreedharan
Corporate Research and Development Centre, HLL Lifecare Limited, Thiruvananthapuram 695 017, Kerala, India
1 shared publication - Lissy Kalliyana Krishnan
Division of Thrombosis Research, Department of Applied Biology, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, India
1 shared publication - Ranjith S
Division of Thrombosis Research, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences &Technology, Trivandrum, Kerala, India
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 133, 110967
Sustained release of curcumin from fibrin matrix induces cancer cell death and immunomodulation
- 1 January 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 133, 110967
Open AccessSustained release of curcumin from fibrin matrix induces cancer cell death and immunomodulation
- RetractedOpen Access
- 26 August 2016
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 7, 1307
RETRACTED: Pseudopyronine B: A Potent Antimicrobial and Anticancer Molecule Isolated from a Pseudomonas mosselii
In continuation of our search for new bioactive compounds from soil microbes, a fluorescent Pseudomonas strain isolated from paddy field soil of Kuttanad, Kerala, India was screened for the production of bioactive secondary metabolites. This strain was identified as Pseudomonas mosselii through 16S rDNA gene sequencing followed by BLAST analysis and the bioactive metabolites produced were purified by column chromatography (silica gel) and a pure bioactive secondary metabolite was isolated. This bioactive compound was identified as Pseudopyronine B by NMR and HR-ESI-MS. Pseudopyronine B recorded significant antimicrobial activity especially against Gram-positive bacteria and agriculturally important fungi. MTT assay was used for finding cell proliferation inhibition, and Pseudopyronine B recorded significant antitumor activity against non-small cell lung cancer cell (A549), and mouse melanoma cell (B16F10). The preliminary MTT assay results revealed that Pseudopyronine B recorded both dose- and time-dependent inhibition of the growth of test cancer cell lines. Pseudopyronine B induced apoptotic cell death in cancer cells as evidenced by Acridine orange/ethidium bromide and Hoechst staining, and this was further confirmed by flow cytometry analysis using Annexin V. Cell cycle analysis also supports apoptosis by inducing G2/M accumulation in both A549 and B16F10 cells. Pseudopyronine B treated cells recorded significant up-regulation of caspase 3 activity. Moreover, this compound recorded immunomodulatory activity by enhancing the proliferation of lymphocytes. The production of Pseudopyronine B by P. mosselii and its anticancer activity in A549 and B16F10 cell lines is reported here for the first time. The present study has a substantial influence on the information of Pseudopyronine B from P. mosselii as potential sources of novel drug molecule for the pharmaceutical companies, especially as potent antimicrobial and anticancer agent.
- 26 August 2016
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 7, 1307
RetractedOpen AccessRETRACTED: Pseudopyronine B: A Potent Antimicrobial and Anticancer Molecule Isolated from a Pseudomonas mosselii
In continuation of our search for new bioactive compounds from soil microbes, a fluorescent Pseudomonas strain isolated from paddy field soil of Kuttanad, Kerala, India was screened for the production of bioactive secondary metabolites. This strain was identified as Pseudomonas mosselii through 16S rDNA gene sequencing followed by BLAST analysis and the bioactive metabolites produced were purified by column chromatography (silica gel) and a pure bioactive secondary metabolite was isolated. This bioactive compound was identified as Pseudopyronine B by NMR and HR-ESI-MS. Pseudopyronine B recorded significant antimicrobial activity especially against Gram-positive bacteria and agriculturally important fungi. MTT assay was used for finding cell proliferation inhibition, and Pseudopyronine B recorded significant antitumor activity against non-small cell lung cancer cell (A549), and mouse melanoma cell (B16F10). The preliminary MTT assay results revealed that Pseudopyronine B recorded both dose- and time-dependent inhibition of the growth of test cancer cell lines. Pseudopyronine B induced apoptotic cell death in cancer cells as evidenced by Acridine orange/ethidium bromide and Hoechst staining, and this was further confirmed by flow cytometry analysis using Annexin V. Cell cycle analysis also supports apoptosis by inducing G2/M accumulation in both A549 and B16F10 cells. Pseudopyronine B treated cells recorded significant up-regulation of caspase 3 activity. Moreover, this compound recorded immunomodulatory activity by enhancing the proliferation of lymphocytes. The production of Pseudopyronine B by P. mosselii and its anticancer activity in A549 and B16F10 cell lines is reported here for the first time. The present study has a substantial influence on the information of Pseudopyronine B from P. mosselii as potential sources of novel drug molecule for the pharmaceutical companies, especially as potent antimicrobial and anticancer agent.